TIPARP and neoplasm: The effectiveness of PARP7 inhibitor-induced tumour regression therefore relies on an intact IFN-I signalling pathway and an increased infiltration of CD8+ T cells (Refs 5, 6, 7, 8, 9, 10, 11, 12, 13).